利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.03 秒)

    MEANS AND METHODS FOR THE TREAMENT OF TUMOROUS DISEASES
    13.
    发明申请
    MEANS AND METHODS FOR THE TREAMENT OF TUMOROUS DISEASES 审中-公开
    肿瘤疾病的手段和方法

    公开(公告)号：US20130095103A1

    公开(公告)日：2013-04-18

    申请号：US13219120

    申请日：2011-08-26

    申请人： Patrick Baeuerle ,  Peter Kufer ,  Matthias Klinger ,  Eugen Leo

    发明人： Patrick Baeuerle ,  Peter Kufer ,  Matthias Klinger ,  Eugen Leo

    IPC分类号： A61K39/395 ,  A61K45/06

    CPC分类号： A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2809 ,  C07K2317/31

    摘要： Provided are pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject in the need thereof and the use of said bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia, whereby said construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.

    摘要翻译： 提供了用于预防，治疗或改善无痛或侵袭性B细胞非霍奇金淋巴瘤（B NHL）和B细胞白血病的药物方法和方法，其包括在需要时向受试者施用双特异性单链抗体构建体， 使用所述双特异性单链抗体构建体来制备用于预防，治疗或改善无痛或侵袭性B细胞非霍奇金淋巴瘤（B NHL）和B细胞白血病的药物组合物，其中所述构建体将被施用于 至少1周，指定日剂量。 此外，本发明涉及包含根据本发明使用的双特异性单链抗体构建体的试剂盒。

    Nuclear hormone receptor fluorescence polarization assay
    15.
    发明授权
    Nuclear hormone receptor fluorescence polarization assay 失效
    核激素受体荧光偏振测定

    公开(公告)号：US06555326B1

    公开(公告)日：2003-04-29

    申请号：US08975614

    申请日：1997-11-21

    申请人： Kevin Lustig ,  Patrick Baeuerle ,  Holger Beckmann ,  Jin-Long Chen ,  Bei Shan

    发明人： Kevin Lustig ,  Patrick Baeuerle ,  Holger Beckmann ,  Jin-Long Chen ,  Bei Shan

    IPC分类号： G01N3352

    CPC分类号： G01N33/542 ,  G01N33/74 ,  G01N2333/575 ,  G01N2333/70567

    摘要： Methods for identifying modulators of nuclear hormone receptor function comprise the steps of (a) forming a mixture comprising a nuclear hormone receptor, a peptide sensor and a candidate agent, but not a natural coactivator protein of the receptor, wherein the sensor provides direct, in vitro binding to the receptor under assay conditions; (b) measuring an agent-biased binding of the sensor to the receptor; and (c) comparing the agent-biased binding with a corresponding unbiased binding of the sensor to the receptor. In particular embodiments, the sensor comprises an amphipathic alpha helix nuclear hormone interacting domain comprising a recited nuclear hormone transcriptional coactivator motif sequence, the sensor is present at sub-micromolar concentration, the binding reaction occurs in solution, the sensor comprises a fluorescent label and the measuring step comprises detecting fluorescence polarization of the label. Reagents include labeled sensor peptides and reaction mixtures consisting essentially of nuclear hormone receptor, a peptide and a candidate agent.

    摘要翻译： 用于鉴定核激素受体功能调节剂的方法包括以下步骤：（a）形成包含核激素受体，肽传感器和候选试剂但不是受体的天然共激活蛋白的混合物，其中所述传感器直接提供 在测定条件下与受体的体外结合; （b）测量传感器与受体的药剂偏置结合; 和（c）将代理偏好的结合与传感器与受体的相应的无偏见的结合进行比较。 在具体实施方案中，传感器包括包含所述核激素转录辅激动子序列的两亲性α螺旋核激素相互作用结构域，所述传感器以亚微摩尔浓度存在，所述结合反应发生在溶液中，所述传感器包含荧光标记和 测量步骤包括检测标签的荧光偏振。 试剂包括标记的传感器肽和基本上由核激素受体，肽和候选试剂组成的反应混合物。

    IKAP nucleic acids
    18.
    发明授权
    IKAP nucleic acids 失效
    IKAP核酸

    公开(公告)号：US5891719A

    公开(公告)日：1999-04-06

    申请号：US971244

    申请日：1997-11-16

    申请人： Lucie Cohen ,  Patrick Baeuerle

    发明人： Lucie Cohen ,  Patrick Baeuerle

    IPC分类号： A61K38/00 ,  C07K14/47 ,  C12N5/10 ,  C12N15/11 ,  C12N15/12

    CPC分类号： C07K14/4705 ,  A61K38/00

    摘要： The invention provides methods and compositions relating to IKAP proteins which regulate cellular signal transduction and transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKAP encoding nucleic acids or purified from human cells. The invention provides isolated IKAP hybridization probes and primers capable of specifically hybridizing with the disclosed IKAP genes, IKAP-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

    摘要翻译： 本发明提供了涉及调节细胞信号转导和转录激活的IKAP蛋白质以及相关核酸的方法和组合物。 可以从所公开的IKAP编码核酸的转化的宿主细胞重组产生多肽或从人细胞纯化。 本发明提供了能够与所公开的IKAP基因，特异性抗体IKAP特异性结合剂特异性杂交的分离的IKAP杂交探针和引物，以及在诊断，治疗和生物制药工业中制备和使用本发明组合物的方法。

    De-immunized (poly)peptide constructs
    19.
    发明申请
    De-immunized (poly)peptide constructs 失效
    去免疫（多）肽构建体

    公开(公告)号：US20060062780A1

    公开(公告)日：2006-03-23

    申请号：US10503590

    申请日：2003-02-12

    申请人： Marcel Zocher ,  Torsten Dreier ,  Patrick Baeuerle

    发明人： Marcel Zocher ,  Torsten Dreier ,  Patrick Baeuerle

    IPC分类号： A61K39/395 ,  A61K38/17 ,  C07K16/42 ,  C07K14/47 ,  C12P21/06

    CPC分类号： C07K16/2878 ,  A61K38/00 ,  A61K39/39 ,  A61K2039/55516 ,  A61K2039/55561 ,  C07K2319/00 ,  C07K2319/30 ,  Y02A50/466

    摘要： The present invention relates to a (poly)peptide construct consisting of at least two domains of at least two pluralities of domains wherein one of said domains or pluralities of domains comprises a de-immunized autoreactive antigen or (a) fragment(s) thereof specifically recognized by the Ig receptors of an autoreactive B-cells and wherein a/the further domain or plurality of domains comprises an effector molecule capable of interacting with and/or of activating NK-cells, T-cells, macrophages, monocytes and/or granulocytes. Preferably, said (poly)peptide construct consisting of at least two domains comprises a de-immunized autoreactive antigen or (a) fragment which is MOG or (a) fragment(s) thereof and a second domain comprising an effector molecule is an anti-CD3 receptor or an Fc-part of an immunoglobulin. The invention also relates to compositions comprising the compounds of the invention. Described is also the use of the afore-mentioned (poly)peptide construct and further compounds for the preparation of a pharmaceutical composition for the treatment and/or prevention of an autoimmune disease. In addition, the present invention relates to method for treating, ameliorating and/or preventing of an autoimmune disease.

    摘要翻译： 本发明涉及由多个结构域至少两个结构域组成的（多）肽构建体，其中所述结构域或多个结构域之一包含去免疫的自身反应性抗原或（a）其特异性片段 由自身反应性B细胞的Ig受体识别，并且其中一个或多个结构域包含能够与NK细胞，T细胞，巨噬细胞，单核细胞和/或粒细胞相互作用和/或激活的效应分子 。 优选地，由至少两个结构域组成的所述（多）肽构建体包含去免疫的自身反应性抗原或（a）作为MOG或（a）其片段的片段，并且包含效应分子的第二结构域是抗 - CD3受体或免疫球蛋白的Fc部分。 本发明还涉及包含本发明化合物的组合物。 还描述了上述（多）肽构建体和其它化合物用于制备用于治疗和/或预防自身免疫疾病的药物组合物的用途。 此外，本发明涉及治疗，改善和/或预防自身免疫性疾病的方法。

    De-immunized MOG (poly)peptide constructs
    20.
    发明授权
    De-immunized MOG (poly)peptide constructs 失效
    去免疫的MOG（多）肽构建体

    公开(公告)号：US07323440B2

    公开(公告)日：2008-01-29

    申请号：US10503590

    申请日：2003-02-12

    申请人： Marcel Zocher ,  Torsten Dreier ,  Patrick Baeuerle

    发明人： Marcel Zocher ,  Torsten Dreier ,  Patrick Baeuerle

    IPC分类号： A61K38/16

    CPC分类号： C07K16/2878 ,  A61K38/00 ,  A61K39/39 ,  A61K2039/55516 ,  A61K2039/55561 ,  C07K2319/00 ,  C07K2319/30 ,  Y02A50/466

    摘要： The present invention relates to a (poly)peptide construct consisting of at least two domains of at least two pluralities of domains wherein one of said domains or pluralities of domains comprises a de-immunized autoreactive antigen or (a) fragment(s) thereof specifically recognized by the Ig receptors of an autoreactive B-cells and wherein a/the further domain or plurality of domains comprises an effector molecule capable of interacting with and/or of activating NK-cells, T-cells, macrophages, monocytes and/or granulocytes. Preferably, said (poly)peptide construct consisting of at least two domains comprises a de-immunized autoreactive antigen or (a) fragment which is MOG or (a) fragment(s) thereof and a second domain comprising an effector molecule is an anti-CD3 receptor or an Fc-part of an immunoglobulin. The invention also relates to compositions comprising the compounds of the invention. Described is also the use of the afore-mentioned (poly)peptide construct and further compounds for the preparation of a pharmaceutical composition for the treatment and/or prevention of an autoimmune disease. In addition, the present invention relates to method for treating, ameliorating and/or preventing of an autoimmune disease.

    摘要翻译： 本发明涉及由多个结构域至少两个结构域组成的（多）肽构建体，其中所述结构域或多个结构域之一包含去免疫的自身反应性抗原或（a）其特异性片段 由自身反应性B细胞的Ig受体识别，并且其中一个或多个结构域包含能够与NK细胞，T细胞，巨噬细胞，单核细胞和/或粒细胞相互作用和/或激活的效应分子 。 优选地，由至少两个结构域组成的所述（多）肽构建体包含去免疫的自身反应性抗原或（a）作为MOG或（a）其片段的片段，并且包含效应分子的第二结构域是抗 - CD3受体或免疫球蛋白的Fc部分。 本发明还涉及包含本发明化合物的组合物。 还描述了上述（多）肽构建体和其它化合物用于制备用于治疗和/或预防自身免疫疾病的药物组合物的用途。 此外，本发明涉及治疗，改善和/或预防自身免疫性疾病的方法。